Company Overview - STRATA Skin Sciences, Inc. is a medical technology company focused on developing and commercializing products for dermatological conditions, utilizing expertise in laser technology [1] Financial Performance - STRATA's Return on Invested Capital (ROIC) is -58.59%, while its Weighted Average Cost of Capital (WACC) is 7.71%, resulting in a ROIC to WACC ratio of -7.60, indicating inefficiencies in capital utilization [2] - Comparatively, Sensus Healthcare, Inc. has a ROIC of -4.47% and a WACC of 10.28%, leading to a ROIC to WACC ratio of -0.44, which is the highest among its peers, suggesting better capital efficiency [3] - Other peers like Soleno Therapeutics, Inc. and SenesTech, Inc. have ROIC to WACC ratios of -13.40 and -12.05, respectively, indicating significant challenges in generating returns above their cost of capital [4] - Xcel Brands, Inc. also faces issues with a ROIC to WACC ratio of -8.94, highlighting inefficiencies in capital management [4] - Overall, all companies, including STRATA, are struggling to generate returns above their cost of capital, with Sensus Healthcare standing out for its relatively better performance [5]

MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered diagnostics, today unveiled its breakthrough artificial intelligence platform for the detection and monitoring of basal cell carcinoma (BCC), the most common form of skin cancer. Though rarely fatal, untreated BCC can cause severe disfigurement, local tissue invasion, and costly surgeries. ...

Accessibility StatementSkip Navigation Leading breast surgical oncologist Dr. Amelia Tower to present on wide-field optical coherence tomography for margin visualization during breast conserving surgery TORONTO and DALLAS, Sept. 19, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced that Dr. Amelia Tower, a leading breast surgical oncologist will present today at the 2025 Annual Clinica ...

MESA, ARIZONA / ACCESS Newswire / September 18, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a leader in AI-powered preventive healthcare, today announced a major advancement in dermatology: an artificial intelligence platform designed to revolutionize the early detection of melanoma, the deadliest form of skin cancer. Melanoma accounts for only 1% of skin cancers but causes the majority of skin cancer deaths worldwide. ...

Safe Supply Streaming Co Ltd. Secures Canadian Distribution Agreement with NIRLAB SA to Provide Advanced Drug Detection Technology to Indigenous CommunitiesSeptember 18, 2025 7:13 AM EDT | Source: Safe Supply Streaming Co Ltd.Toronto, Ontario--(Newsfile Corp. - September 18, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health and safety, and rapid response technologies, today announced it has signed a Canadian distri ...

Core Insights - ONWARD Medical N.V. has published significant findings in Nature and Nature Medicine, supporting the efficacy of its investigational ARC-IM System for treating blood pressure instability in individuals with spinal cord injuries (SCI) [1][6][7] Group 1: Clinical Findings - Multi-year clinical feasibility studies demonstrated that participants receiving ARC-IM Therapy experienced immediate and substantial increases in blood pressure, along with a reduction in hypotensive symptoms, leading to improved quality of life and greater engagement in daily activities [2][3] - The studies involved 14 participants from leading neurorehabilitation clinics across Switzerland, Canada, and the Netherlands, showing consistent benefits across all sites for up to two years post-implant [2][3] - Participants reported reduced fatigue, improved bowel management, and increased tolerance for upright postures, with many able to reduce or discontinue traditional low blood pressure treatments [3] Group 2: Mechanistic Insights - Research identified the neuronal architecture of the spinal cord that contributes to autonomic dysreflexia (AD), a dangerous condition characterized by uncontrolled high blood pressure [4][5] - Electrical stimulation targeting the "Hemodynamic Hotspot" in the spinal cord was shown to effectively regulate blood pressure by activating a competing neuronal architecture [4][8] Group 3: Market Implications - The majority of individuals with SCI experience blood pressure instability, with 78% of those with tetraplegia diagnosed with orthostatic hypotension, yet only 28% receiving treatment [5] - The findings from the publications validate ONWARD's commitment to addressing critical autonomic functions affected by SCI and support the upcoming Empower BP global pivotal study, which aims to further assess the safety and efficacy of the ARC-IM System [6][9] Group 4: Future Developments - The FDA has approved an investigational device exemption (IDE) for the ARC-IM System, allowing the initiation of the Empower BP study, which will involve at least 60 participants across 20 research centers in the US, Canada, and Europe [9] - The study will focus on participants with spinal cord injuries at levels C2-T6 and severities of AIS A-D, with first patient enrollment expected before the end of the year [9] Group 5: Company Overview - ONWARD Medical is a leading neurotechnology company focused on developing therapies to restore movement and independence in individuals with spinal cord injuries and other movement disabilities [11][12] - The company has received 10 Breakthrough Device designations from the FDA and has developed the ARC-EX System, which is already cleared for commercial sale in the US and Europe [11]

Group 1 - Michael Reitermann has been appointed as Delegate of the Board of Directors and interim CEO of Ascom Holding AG, taking over from Nicolas Vanden Abeele, who is leaving after nearly four years [1][3][5] - The Board of Directors aims to accelerate the execution of its current strategy and exploit growth potential, particularly in the USA and Canada [3] - An internal and external search for a new CEO has been initiated while Reitermann serves as interim CEO [3] Group 2 - Laurent Dubois has been nominated as the new Chairman of the Board of Directors, to be elected at the Annual General Meeting in 2026, following the retirement of Dr. Valentin Chapero Rueda [2][6] - Dubois has over 30 years of leadership experience in various sectors, including industry, consulting, B2B technology, and healthcare [7] - The Board of Directors will reduce its size from six to five members effective from the Annual General Meeting in 2026 [8]

Core Viewpoint - GE HealthCare Technologies (GEHC) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system focuses on changes in earnings estimates, which are crucial for assessing a company's future earnings potential and stock price movements [2][5]. - The Zacks Consensus Estimate for GE HealthCare has increased by 12.7% over the past three months, reflecting analysts' growing confidence in the company's earnings outlook [9]. Impact of Institutional Investors - Changes in earnings estimates are closely correlated with stock price movements, largely due to institutional investors who adjust their valuations based on these estimates [5][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional buying that drives stock prices up [5]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - GE HealthCare's upgrade to Zacks Rank 1 places it in the top 5% of stocks covered by Zacks, suggesting strong potential for market-beating returns in the near term [10][11].

Company Overview - Zimmer Biomet Holdings, Inc. (ZBH) has a market capitalization of $19.6 billion and specializes in musculoskeletal healthcare solutions, including orthopedic reconstructive implants and various medical technologies [1] - The company is classified as a "large-cap" stock, which typically includes companies valued over $10 billion [2] Stock Performance - ZBH shares have decreased by 13.6% from their 52-week high of $114.72, while returning 7.6% over the past three months, in line with the Dow Jones Industrials Average [3] - Year-to-date, ZBH stock has declined by 6.2%, underperforming the Dow Jones Industrials Average, which has increased by 7.6% [4] - Over the past 52 weeks, ZBH shares have dropped 7.7%, compared to a 9.9% rise in the Dow Jones Industrials Average [4] - Despite recent declines, ZBH stock has been trading above its 50-day moving average since early August [5] Recent Financial Results - On August 7, ZBH shares rose nearly 8% following the release of better-than-expected Q2 2025 results, reporting adjusted EPS of $2.07 and revenue of $2.08 billion [6] - The company raised its 2025 adjusted EPS forecast to between $8.10 and $8.30, exceeding analyst expectations, and reduced anticipated tariff headwinds to approximately $40 million [6] Competitive Landscape - ZBH has underperformed compared to its rival, Penumbra, Inc. (PEN), which has seen a YTD increase of 10.7% and a 52-week increase of 40.1% [7] - Analysts maintain a moderately optimistic outlook for ZBH, with a consensus rating of "Moderate Buy" from 27 analysts and a mean price target of $110.96, indicating an 11.9% premium to current levels [7]

Core Insights - BD (Becton, Dickinson and Company) has successfully placed its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, marking a significant milestone in the adoption of its single-cell multiomics analysis technology [1][2]. Company Overview - BD is recognized as one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery [5]. - The company employs over 70,000 individuals and operates in virtually every country, partnering with organizations to tackle global health challenges [5]. Product Highlights - The BD Rhapsody™ System, introduced in 2017, has been cited in over 700 peer-reviewed publications, demonstrating its impact in the scientific community [2]. - The latest version of the BD Rhapsody™, launched in 2023, features advanced sample processing and cell capture technologies, enhancing the efficiency of next-generation sequencing applications [2]. - Upcoming innovations include the BD OMICS-One™ WTA Next Assay for unlocking genetic information at a lower cost and BD® OMICS-Guard Cryo for sample preservation [6]. Market Demand - The rapid adoption of the BD Rhapsody™ System reflects a critical need for high-performing multiomic assays that maintain data quality while being cost-effective [3]. - The system is positioned to work seamlessly with leading cell sorters and analyzers, indicating a comprehensive end-to-end solution for single-cell analysis [3]. Research and Development - Research conducted by Dr. Andrew Conway Morris at Addenbrooke's Hospital aims to understand immune cell signaling pathways, with the BD Rhapsody™ System facilitating advanced analysis at the single-cell level [2]. - The company continues to innovate its workflows and product offerings to meet the evolving scientific needs [3]. Upcoming Events - The BD Rhapsody™ System will be showcased at the 2025 Annual Meeting of the American Society of Human Genetics and at Advancing Precision Medicine [4].